Evidence map›Paper›PMID 39365993›Full record

ArticleBlood advances2025

The common VTE-protective G haplotype of F5 increases factor V-short, TFPI function, and risk of bleeding.

Matthew C Sims, Magdalena Gierula, Jonathan C Stephens, Alex Tokolyi, Luca Stefanucci, Elodie Persyn, Luanluan Sun, Janine H Collins, Emma E Davenport, Emanuele Di Angelantonio and 11 more

Abstract read
In one paragraph

Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Matthew C SimsDepartment of Haematology, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0003-4503-0265
Magdalena GierulaDepartment of Immunology and Inflammation, Centre for Haematology, Imperial College London, London, United Kingdom.
Jonathan C StephensDepartment of Haematology, University of Cambridge, Cambridge, United Kingdom.
Alex TokolyiWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.ORCID 0000-0003-4222-7484
Luca StefanucciDepartment of Haematology, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-4352-1151
Elodie PersynDepartment of Public Health and Primary Care, British Heart Foundation Cardiovascular Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0001-9104-1972
Luanluan SunDepartment of Public Health and Primary Care, British Heart Foundation Cardiovascular Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom.
Janine H CollinsDepartment of Haematology, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-8716-3261
Emma E DavenportWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
Emanuele Di AngelantonioBritish Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Kate DownesDepartment of Haematology, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0003-0366-1579
Michael InouyeBritish Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Dirk S PaulDepartment of Public Health and Primary Care, British Heart Foundation Cardiovascular Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-8230-0116
Will ThomasDepartment of Haematology, Cambridge University Hospitals National Health Service Foundation Trust, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Alexander ToliosDepartment of Transfusion Medicine and Cell Therapy, Medical University of Vienna, Vienna, Austria.ORCID 0000-0001-9163-7127
Willem H OuwehandDepartment of Haematology, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-7744-1790
Nicholas S GleadallDepartment of Haematology, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-1132-1059
James T B CrawleyDepartment of Immunology and Inflammation, Centre for Haematology, Imperial College London, London, United Kingdom.ORCID 0000-0002-6723-7841
Adam S ButterworthBritish Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.ORCID 0000-0002-6915-9015
Mattia FrontiniDepartment of Haematology, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0001-8074-6299
Josefin AhnströmDepartment of Immunology and Inflammation, Centre for Haematology, Imperial College London, London, United Kingdom.ORCID 0000-0001-5313-6508

Funding

Medical Research Council MR/P02002X/1Wellcome Trust
6 · The paper itself

Abstract

abstractThe G haplotype is a group of co-inherited single nucleotide variants in the F5 gene that reduce venous thromboembolism (VTE) risk. Although 7% of the population is homozygous for the G haplotype (F5-G/G), the underlying mechanism of VTE protection is poorly understood. Using RNA sequencing data from 4651 blood donors in the INTERVAL study, we detected a rare excision event at the factor V (FV)-short splice sites in 5% of F5-G/Gs carriers as compared with 2.16% of homozygotes for the F5 reference sequence (F5-ref; P = .003). Highly elevated (∼10-fold) FV-short, a FV isoform that lacks most of the B-domain, has been linked with increased tissue factor inhibitor α (TFPIα) levels in rare hemorrhagic diathesis, including East Texas bleeding disorder. To ascertain whether the enhanced FV-short splicing seen in F5-G/G INTERVAL participants translated to increased plasma FV-short levels, we analyzed plasma samples from 7 F5-G/G and 13 F5-ref individuals in a recall-by-genotype study. A ∼2.2-fold higher amount of FV-short was found in a plasma pool from F5-G/G participants when compared with the pool of F5-refs (P = .029), but there was no difference in the total FV levels. Although no significant difference in TFPI levels were found, F5-G/Gs showed a ∼1.4-fold TFPI-dependent increase in lag time to thrombin generation than F5-refs (P = .0085). Finally, in an analysis of 117 699 UK Biobank participants, we discovered that, although being protective against VTE, the G haplotype also confers an increase in bleeding episodes (P = .011). Our study provides evidence that the effect of the common G haplotype is mediated by the FV-short/TFPI pathway.

Indexed as

Factor VHaplotypesHemorrhageLipoproteinsVenous ThromboembolismFemaleGenetic Predisposition to DiseaseHumansMalePolymorphism, Single NucleotideRisk FactorsFactor Vlipoprotein-associated coagulation inhibitorLipoproteins

Identifiers

PMID39365993
PMCPMC11750501

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.